Merck KGaA taps Cyclica for AI-based screening of protein-drug interactions

In Silico
Cyclica recently signed a similar compound-screening agreements with Bayer and WuXi AppTec. (Pixabay/Geralt)

Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.

The yearlong agreement will allow the German biotech to evaluate the mechanisms of action and safety profiles of a number of its small molecules in the discovery and early development stages, as well as explore any additional applications for its drugs.

Cyclica’s Ligand Express platform models interactions between small-molecule drugs and repositories of the human body’s protein structures to determine pharmacological profiles and potential side effects, including on- and off-target effects, and prioritize lead candidates.

WEBINAR

Webinar: The Key to Continuous Compliance for Medical Device Software Developers

Risk is not an option in medical device software development. You need to mitigate time-to-market, FDA, and security risks, or you could be facing a costly recall or software update. Attend this webinar to learn how to use static analysis to ensure continuous compliance with industry standards and regulatory requirements, improve security for increasingly connected medical devices, and enforce corporate and industry coding rules and best practices.

“A key part of our R&D strategy is to progress highly promising compounds as efficiently and rapidly as possible,” Friedrich Rippmann, Merck’s director of computational chemistry & biology, said in a statement.

RELATED: WuXi AppTec and Cyclica to collaborate on drug discovery efforts

“Assessing new technologies is central to how we will advance our discovery programs, and artificial intelligence applications like Ligand Express will provide important insights to enhance how we think about target identification to support phenotypic screening and off-target profiling in general,” Rippmann added.

Cyclica recently signed a similar compound-screening agreement with Bayer, launching a multiphase collaboration to investigate off-target effects of small molecules and build predictive, in silico drug models.

“Current experimental protein screening approaches can take up to a year, making it virtually impossible to do this for multiple compounds,” said Cyclica President and CEO Naheed Kurji. “We see this as a specific opportunity for cloud-based and AI-augmented technologies to drive drug discovery more efficiently.”

Suggested Articles

Cornell researchers found that inhibiting a long noncoding RNA called SAF caused HIV-infected cells to self-destruct.

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.